Bangolo Ayrton, Tran Hadrian Hoang-Vu, Alqinai Budoor, Goyal Rishabh, Ahmed Shehwar, Qasim Aamna, Rojas Gabriela, Madan Shubham, Barbosa Helena, Mustafa Zainab, Waseem Risham, Ingersoll Gabriel, Khan Hamza, Guzzetti Alison, Daniel Jonathan, Parkar Samiya, Tiwari Aakriti, Lafleur Sarah, Cingapagu Rajasekhar, Amasyali Saliha Y, Chen Eric Pin-Shiuan, Weissman Simcha
Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ 07601, USA.
Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA.
Diseases. 2025 Aug 12;13(8):256. doi: 10.3390/diseases13080256.
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide, with survival outcomes influenced by a range of demographic and pathological factors. While cirrhosis is a well-established risk factor, recent evidence shows that HCC can also develop in patients with only mild to moderate liver fibrosis. However, there is limited understanding of how fibrosis severity interacts with other clinical variables, such as patient age, to affect mortality. This study aims to explore how fibrosis scores relate to both overall and cancer-specific mortality in US HCC patients, with an emphasis on how this relationship may shift across different age groups.
We utilized data from the Surveillance, Epidemiology, and End Results (SEER) database to identify 15,796 adult patients diagnosed with HCC between 2010 and 2021. Baseline demographics, disease characteristics, and treatment variables were examined. Mortality outcomes were evaluated using Cox proportional hazard regression. Variables significant at < 0.1 in univariate analysis were included in multivariate models to identify independent predictors of mortality (with hazard ratios [HRs] > 1 signifying increased risk). A secondary analysis assessed how age modifies the association between fibrosis score and mortality.
The study population was predominantly male (77.2%), with most patients aged 60-79 (59.6%) and presenting with localized disease (61%). A majority had advanced liver fibrosis or cirrhosis (81.7%) and lived in large urban areas (62.9%). Crude comparisons indicated that male sex, older age, single status, advanced tumor stage, lower income, and cirrhosis were linked to worse outcomes. In adjusted models, independent predictors of increased mortality included male sex, older age, unmarried status, and more advanced disease stage. Receipt of surgery or chemotherapy was associated with a lower risk of death. Notably, the influence of fibrosis on mortality was found to be greater in older patients than in their younger counterparts.
This analysis identifies key prognostic indicators in HCC and suggests that the relationship between fibrosis and survival is not uniform across age groups. These findings support the need for age-specific clinical management strategies and highlight the potential benefit of early detection and appropriate interventions, even in non-cirrhotic patients.
肝细胞癌(HCC)仍然是全球癌症相关死亡的主要原因,生存结果受到一系列人口统计学和病理因素的影响。虽然肝硬化是一个公认的危险因素,但最近的证据表明,HCC也可在仅有轻度至中度肝纤维化的患者中发生。然而,对于纤维化严重程度如何与其他临床变量(如患者年龄)相互作用以影响死亡率,人们的了解有限。本研究旨在探讨纤维化评分与美国HCC患者的总体死亡率和癌症特异性死亡率之间的关系,重点关注这种关系在不同年龄组中可能如何变化。
我们利用监测、流行病学和最终结果(SEER)数据库的数据,确定了2010年至2021年间确诊为HCC的15796例成年患者。检查了基线人口统计学、疾病特征和治疗变量。使用Cox比例风险回归评估死亡率结果。单变量分析中P<0.1的变量被纳入多变量模型,以确定死亡率的独立预测因素(风险比[HRs]>1表示风险增加)。二次分析评估了年龄如何改变纤维化评分与死亡率之间的关联。
研究人群以男性为主(77.2%),大多数患者年龄在60 - 79岁之间(59.6%),表现为局限性疾病(61%)。大多数患者有晚期肝纤维化或肝硬化(81.7%),居住在大城市地区(62.9%)。粗略比较表明,男性、老年、单身状态、肿瘤晚期、低收入和肝硬化与较差的结果相关。在调整模型中,死亡率增加的独立预测因素包括男性、老年、未婚状态和疾病分期更晚。接受手术或化疗与较低的死亡风险相关。值得注意的是,发现纤维化对死亡率的影响在老年患者中比在年轻患者中更大。
本分析确定了HCC的关键预后指标,并表明纤维化与生存之间的关系在不同年龄组中并不一致。这些发现支持了针对特定年龄的临床管理策略的必要性,并强调了早期检测和适当干预的潜在益处,即使在非肝硬化患者中也是如此。